Nineteen diabetic patients with peripheral vascular disease treated with Bradilan (tetranicotinoylfructose) tablets showed cure or improvement in 14 cases with no adverse effect on their diabetic control. It must therefore be considered a useful drug in the treatment of such diabetic patients with peripheral vascular problems.
Get full access to this article
View all access options for this article.
References
1.
AndrewsGJudgeTGWalkeyF (1973) The Action of Tetranicotinoylfructose in Peripheral Vascular Disease. Practitioner211, 83
2.
AnteliffACBouhoutsosJMartinPMorrisT (1974) A Plethysmographie Study of the Effect of Tetranicotinoylfructose (Bradilan) on Digital Blood Flow in Primary and Secondary Raynaud's Phenomenon. Angiohgy25, 31
3.
DonnanF de S (1974) A Double-Blind Trial of Bradilan (Tetranicotinoylfructose) in Perniosis in General Practice. Journal of International Medical Research2, 56
4.
GibelliAFrardoliGGiarolaP (1966) The Fibrinolytic Activity of Tetranicotinoylfructosc in Aged Patients. Gazzetta Internazionale di Medicina e Chirurgia71, 240
5.
GurianHAdlersbertD (1959) The Effect of Large Doses of Nicotinic Acid on Circulation Lipids and Carbohydrate Tolerance. American Journal of Medical Science237, 12
6.
HoltiGNewellDJPooleHG (1971) Tetranicotinoylfructose in Disorders of Digital Blood Flow. Practitioner207, 654
7.
KissebahA HAdamsPWHarriganPWynnV (1974) The Mechanism of Action of Clofibrate and Tetranicotinoylfructose (Bradilan) in the Kinetics of Plasma Free Fatty Acid and Triglyceride Transport in Type IV and V Hypertriglyceridaemia. European Journal of Clinical Investigation4, 163
8.
MolnarGDBergeKGRosevearJWMcGuckinWFAchorRWP (1961) The Effect of Nicotinic Acid in Diabetes Mellitus. Metabolism13, 181
